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Summary. Urokinase-type plasminogen activator receptor
(UPA-R-CD87) is a GPI-anchored membrane protein which
promotes the generation of plasmin on the surface of many
cell types, probably facilitating cellular extravasation and
tissue invasion. A flow cytometric quantitative analysis of
expression levels for UPA-R was performed on fresh blast cells
from patients with acute myeloid leukaemia (AML, n ¼ 74),
acute lymphoblastic leukaemia (ALL, n ¼ 24), and bipheno-
typic leukaemia (BAL, n ¼ 3) using two CD87 monoclonal
antibodies (McAbs) (3B10 and VIM5). Peripheral blood and
bone marrow (BM) cells from 15 healthy adults served as
controls. Using 3B10 McAb, UPA-R was expressed (>99%) by
blood monocytes, neutrophils, and BM myelomonocytic
precursors in controls, whereas resting T and B lymphocytes,
and CD34þ cells were UPA-R negative. We also attempted to
clarify whether UPA-R has a role in mediating neutrophil
functions. Oriented locomotion induced by different chemo-
taxins and lysozyme release by granules stimulated with
fMLP or PMA were significantly decreased when UPA-R was
neutralized by CD87 McAb. In contrast, the anti-UPA-R
McAb had no effect on superoxide anion generation of
normal neutrophils. Blasts from AML showed a hetero-
genous pattern of expression for the UPA-R McAbs, with
reactivity strictly dependent on FAB subtype. The highest
UPA-R expression was seen in the M5 group: all patients
tested (n ¼ 20) showed strong positivity for the UPA-R McAb
whereas only 12% (3/24) of ALL patients were CD87
positive, and 2/3 of BAL patients showed a dim expression for
CD87. The number of receptors expressed by blast cells in 6/
74 (8·1%) AML patients was higher than those of normal
samples; in addition, since co-expression of UPA-R and CD34
was not found in normal haemopoietic cells, it may be
postulated that CD87 can be used alone (when over-
expressed) or in combination with CD34 for the detection
of minimal residual disease. Results also indicated that
patients with UPA-receptors >12 × 103 ABC/cell, irrespective
of FAB subtype, had a greater tendency for cutaneous and
tissue infiltration and a higher frequency of chromosome
abnormalities, thus suggesting the concept that cellular
UPA-R content positively correlates with the invasive
potential of AML cells. The combination of higher UPA-R
positivity, abnormalities of chromosome 11, and M5 FAB
morphology may identify a peculiar subset of AML,
characterized by a more aggressive clinical course.
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Urokinase is a specific serine protease which catalyses
plasminogen conversion to plasmin principally within the
extravascular compartments. Plasmin is a broad-spectrum
protease which is able to degrade protein constituents of the
extracellular matrix and adhesion molecules in the peri-
cellular space. As a consequence, these enzymes are thought
to contribute to the invasive properties and metastasis
formation of tumour cells (Bu et al, 1994; Stephens et al,
1996; Lijnen, 1996). Urokinase plasminogen activator
(UPA)-mediated cell surface plasminogen activation occurs
on a specific membrane receptor that can be found in many
cell types including monocytes, granulocytes, a subset of
activated natural killer cells, endothelial cells, fibroblasts,
smooth muscle cells, keratocytes, hepatocytes and placental
trophoblasts, as well as in several tumour cells such as
fibrosarcoma, rhabdomyosarcoma, melanoma, breast, pros-
tate and colon carcinoma, and the U937 leukaemia cell line
(Pyke et al, 1991; Todd et al, 1995; Lanza et al, 1994; Sitrin
et al, 1994). The UPA-receptor (UPA-R) is a specific and
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saturable receptor, composed of a single-chain, highly
glycosylated protein with a molecular weight of 55–60 kD.
CD87 serves as a receptor for pro-UPA and UPA with high
affinity (Kd 10
¹9–10¹10 molar) (Todd et al, 1995). The
protein is linked to the plasma membrane via a glycosyl-
phosphatidylinositol (GPI) anchor and thus has no intra-
cytoplasmic domains; as a consequence, signal transduction
by UPA-R may require an adaptor protein connected to the
cell surface. Since UPA-R is spatially and temporally
associated with cellular structures that regulate cell adhe-
sion and migration, it has been hypothesized that formation
of complexes between UPA-R and integrins such as CD11b
(Mac-1) might provide an integrin mediated link between
UPA-R and the cytoskeleton, thus promoting adhesion
(Gyetko et al, 1994, 1995, 1996; Xue et al, 1994; Plesner
et al, 1994; Cao et al, 1995; Kindezelskii et al, 1996; Simon
et al, 1996). When UPA is complexed to its specific inhibitors
PAI-1 (plasminogen activation inhibitor-1) and PN-1, it is
internalized and degraded through a mechanism requiring
both UPA-R and the a2 macroglobulin receptor. CD87 may
also form a functional linkage with b1, b2, b3 integrins or
with other proteins that have tyrosine kinase activity (Wei
et al, 1996).
Recently, UPA-R cDNA has been cloned and the primary
structure of the protein defined; it consists of 313 amino acid
residues organized in three repeating sequences of approxi-
mately 90 amino acids (Todd et al, 1995). The human CD87
gene has been mapped to chromosome 19q1.3.
At the Fifth International Workshop on Leukocyte
Differentiation Antigens, held in Boston, U.S.A., on 3–7
November 1993, six monoclonal antibodies (McAbs) were
verified as recognizing the UPA-R, and were referred to as
CD87 (CD stands for cluster of differentiation) (Todd et al,
1995; Lanza et al, 1994). Four further CD87 McAbs were
assigned in 1996 at the Sixth International Workshop on
Leukocyte Differentiation Antigens.
The aim of this study was to investigate the cellular
expression and functional role of UPA-R in haemopoietic
cells obtained from healthy adult subjects; in addition, UPA-R
expression was evaluated by flow cytometry in acute
leukaemic blasts, and the results were tentatively correlated
with clinical and biological features of the patients
examined.
MATERIALS AND METHODS
Subjects. Fresh bone marrow (BM) cells obtained from
patients with acute myeloid leukaemia (AML, n ¼ 74), acute
lymphoblastic leukaemia of B-cell phenotype (n ¼ 24), AML
with minimal phenotypic deviation (n ¼ 3), and bipheno-
typic acute leukaemia (n ¼ 3) were investigated within 4 h of
collection ¼ Peripheral blood and bone marrow cells from 15
healthy adult subjects were also included in this study.
Written informed consent was obtained from all study
participants as approved by the institutional review board of
the Hospital.
Diagnosis of leukaemia was based on morphological,
cytochemical, cytogenetics, molecular genetics and immuno-
logical criteria. According to the FAB (French–American–
British) classification, AML patients were distributed as
follows: M0: 7; M1: 12; M2: 20; M3: 4; M4 11; M5: 20. ALL
patients were subdivided into the following immunological
subgroups: pro-B (B-I) (CD19þ, cyCD22þ, CD79aþ, CD10¹),
two cases; common B (B-II): CD10þ, CD19þ, CD22þ, CD79þ,
14 cases; pre-B (B-III): cmþ, CD10þ, CD19þ, CD22þ,
CD79aþ, four cases; mature B (B-IV): SigMþ, CD19þ,
CD22þ, CD79aþ, CD10¹, four cases (Bené et al, 1995).
Patients with acute leukaemia had >50% blasts in the
specimen analysed (mean 69%). The diagnosis of bipheno-
typic leukaemias or acute leukaemia with minimal pheno-
typic deviation was made according to the proposals of the
EGIL group (Bené et al, 1995).
AML patients were treated with a DAT-based induction
regimen, followed by consolidation chemotherapy. Patients
with B-lineage ALL were treated according to a modified VPD
based regimen (vincristine, prednisone, daunorubicin) com-
bined with cytosine-arabinoside, cyclophosphamide and
asparaginase.
Flow cytometry analysis. Whole blood samples and purified
CD34þ cells were analysed with a Facscan flow cytometer
(Becton Dickinson, San José, U.S.A.) equipped with a 15 mW
argon-ion laser. The instrument was calibrated with FITC
(isothyocyanate of fluorescein) and PE (R-phycoerythrin)
beads provided by Becton Dickinson. Data were analysed
with appropriate negative (isotypic) and positive (blood cells
from healthy adult subjects) controls using CellQuest and
Paint-a-Gate research software (Lanza et al, 1993). 20 000
cells were analysed for each sample at a flow rate of
approximately 300 particles per second. The blast cell
population was identified using a combined approach
based on a multicolour analysis and evaluation of light
scattering properties of the cells (forward scatter and side
scatter) (Lanza et al, 1996).
In normal CD34þ bone marrow cells the analysis of UPA-R
expression has been performed using a multiparametric live-
gate approach. In two cases the cytofluorimetric analysis
was also performed on CD34þ cells which were purified
using a positive selection technique (MiniMacs system,
Miltenyi Biotec, Milan, Italy) (Lanza et al, 1997a). CD34þ
progenitor cells mobilized with G-CSF were also analysed by
flow cytometry in 10 healthy subjects.
Flow cytometry data were expressed as percentage of
positivity (using the standard marker approach), as mole-
cules of equivalent soluble fluorochrome (MESF), and as
antibody binding capacity (ABC) (Poncelet et al, 1996).
Based on the analysis of the minimum detection threshold of
our flow cytometry, and on variation in MESF and ABC
values for UPA-R in control and pathological samples
(evaluated within and between different specimens), we
estimated that the lower limit of quantitation was 590
MESF/cell. Below this limit the enumeration of antigenic
determinants per cell was considered unreliable and
unreproducible. However, as stated earlier, the lower limit
of detection was variable and ranged from 0·47 to
0·59 × 103 MESF/cell over a period of 4 years (Papa &
Lanza, 1996; Poncelet et al, 1996; Lanza et al, 1997a). Using
the QIFIKIT assay, the lower limit of detection was 0·9 × 103
ABC/cell.
Immunophenotypic analysis. The immunophenotypic profile
of leukaemic cells was assessed with a Facscan flow cyto-
meter using a large panel of McAbs, including CD13, CD33,
CD15, anti-MPO (MPO-7, CLB-MPO1), anti-lysozyme (LZ-1),
CD34 (HPCA-2), CD11b, CD11c, CD65, CD41, CD61, glyco-
phorin A, CD35, CD117, CD56, Thy-1 (CD90), HLA-DR,
CD38, CD14, CD10, CD19, CD22, CD3, CD5, CD7, cyto-
plasmic (cy) CD3, cyCD22, CD79a, TdT (Becton Dickinson;
Dakopatts, Glostrup, Denmark; Immunotech, Marseille,
France; Serotec, U.K.; Caltag, U.S.).
The concentrations of McAbs were titrated towards a
saturating titre, as assessed by flow cytometry analyses
performed on normal haemopoietic cells and cell lines.
Experiments of single, double and triple staining were
employed in all cases.
MPO and lysozyme measurement was performed using Fix
and Perm fixation- permeabilizing agent (Caltag) (Lanza et al,
1997b). McAbs were used at saturating concentration. In
brief, whole blood (1 × 106 cells) was incubated for 15 min at
room temperature with 100 ml of reagent A (fixation
medium), then washed once with PBS before adding 50 ml
of reagent B (permeabilization reagent) plus anti-MPO or
lysozyme McAb. For the detection of lysozyme, whole blood
cells were washed three times before their treatment with the
permeabilization agents, in order to remove serum lysozyme.
Detection of MPO and lysozyme was performed using a direct
immunofluorescence staining method. To study MPO, we
used a FITC-conjugated anti-MPO McAb (clone: MPO-7,
IgG1 isotype, from DAKO), while reactivity for lysozyme was
evaluated by using a FITC-conjugated anti-lysozyme McAb
(clone: LZ-1, IgG1 isotype, purchased from Caltag).
Monoclonal antibodies to UPA-R. The expression of UPA-R
on normal and leukaemic cells was assessed by using two
different unconjugated McAbs: 3B10 (Mizukami et al, 1990)
and VIM5 (Gadd et al, 1990), the latter was developed in
the laboratory of Professor Walter Knapp (Institute of
Immunology, Vienna, Austria).
Negative controls with isotype-matched non-relevant
McAbs (mouse IgG1, IgG2a, IgM; Dakopatts, Silenus) were
done in all experiments. All the McAbs were utilized using an
indirect immunofluorescence technique. As second step we
employed FITC-conjugated rabbit F(ab0) Ig fragments specific
for mouse Ig (fluorochrome/protein ratio 2·3; Dakopatts).
Human AB serum was added prior to antibody incubation to
avoid non-specific binding of McAbs to Fc receptors. All
samples were further incubated for 10 min with a lysing
buffer (Facslysing solution, Becton Dickinson) to eliminate
red blood cells. Two- and three-colour fluorescence staining
experiments were performed using the PE-conjugated VIM-5
McAb (CD87, Pharmingen, U.S.A.), in combination with
McAbs directed against various surface markers.
Detection of cyUPA-R. For the detection of cytoplasmic (cy)
UPA-R, whole blood cells were permeabilized with Fix and
Perm permeabilization-fixation kit (Caltag), as described
above, and then analysed by flow cytometry. For each
sample, the MESF values of the isotypic control was
subtracted from the MESF values of the positive cell
population. The intracellular content of UPA-R was calcu-
lated by subtracting the fluorescence intensity (expressed
either in the form of mean fluorescence intensity, MFI or
MESF) of surface UPA-R evaluated on unfixed cells from the
total amount of UPA-R detected by flow cytometry after
fixation and permeabilization (Lanza et al, 1997b). CyUPA-R
was analysed on neutrophils and monocytes obtained from
healthy subjects, as well as in acute leukaemic blasts from
AML. All experiments were performed in duplicate.
MESF and ABC calculation. To evaluate the number of
antigenic determinants per cell for the various UPA-R
McAbs, we used FITC quantitative microbead calibration
standards (Quantum 26p beads, Flow Cytometry Standard
Corporation, FCSC, purchased from Walter Occhiena srl,
Torino, Italy) in conjuction with the Quantum Simply
Cellular beads (FCSC, Walter Occhiena) (Poncelet et al,
1996). The use of calibrated microbeads made it possible to
express the flow cytometry data in the form of molecules of
equivalent soluble fluorochrome (MESF) values. The calcula-
tion of MESF was based on the evaluation of the peak
channel expressed by cells and different populations of
microbeads. For each sample the MESF value of the isotypic
control was subtracted from the MESF value of the positive
cell population.
Data were also expressed as Antibody Binding Capacity
(ABC) by using the QIFIKIT test (Dakopatts). This kit
contains a series of beads coated with different, but well-
defined, quantities of mouse monoclonal antibody mole-
cules. These beads mimic cells with different antigen
densities which have been labelled with a primary mouse
monoclonal antibody, isotype IgG, and they serve as a set of
standards to calibrate the fluorescence scale of the flow
cytometer in units of ABC (Poncelet et al, 1996).
For the PE-conjugated VIM5 McAb, Quantum Simply
Cellular beads were used to calculate the number of antigens
per cell (Poncelet et al, 1996).
For each sample the ABC value of the isotypic control was
subtracted from the ABC value of the positive cell population.
The range of ABC values for the various normal haemo-
poietic cells and for leukaemic cells was calculated using the
QIFIKIT assay.
DNA analysis by flow cytometry. The assessment of cellular
DNA content was made with a Facscan flow cytometer
(Becton Dickinson), according to a previously published
method (Lanza et al, 1995). Bromodeoxyuridine incorpora-
tion and a monoclonal antibody against bromodeoxyuridine
(Becton Dickinson) were used to calculate the size of
population of cells in S phase of the cell cycle (Lanza et al,
1995).
Purification of the cells. Cells were obtained from the
blood of healthy subjects and neutrophils were purified
employing the standard techniques of dextran sedimentation
(Pharmacia, Uppsala, Sweden), centrifugation on Ficoll-
Paque (Pharmacia) and hypotonic lysis of contaminating red
cells. The cells were washed twice, resuspended in Krebs-
Ringer-phosphate containing 0·1% w/v glucose (KRPG),
pH 7·4, at a final concentration of 50 × 106 cells/ml and kept
at room temperature until used. The percentage of
neutrophils was 98–100% pure and >99% viable as
determined by Trypan blue exclusion test.
Random locomotion. Random locomotion was evaluated
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using 48-well microchemotaxis chamber (BioProbe, Milan,
Italy) (Spisani et al, 1996), by estimating the distance (mm)
which the leading-front of the cell migrated, using the
method of Zigmond & Hirsch (1973), after 90 min incuba-
tion at 378C. A 3 mm pore-size filter (Millipore, Roma, Italy)
separated upper and lower compartments.
Chemotaxis. Chemotaxis was studied by adding the
chemoattractant to the lower compartment. The chemo-
tactic factors used were: 2 mg/ml casein and 10¹8 M N-
formyl-methionyl-leucyl-phenylalanine (fMLP). Casein
(‘Hammarsten’ Merck, Darmstadt, Germany) stock solution
10 mg/ml in KRPG was diluted before use in KRPG
containing 1 mg/ml bovine serum albumin (KRPG-A);
fMLP (Sigma Chemical Co., St Louis, Mo., U.S.A.) stock
solution 10¹2 M in dimethylsulphoxide (DMSO) was diluted
before use in KRPG-A. The DMSO did not interfere with any
of the biological assays performed.
Superoxide anion (O¹2 ) production. The superoxide anion
production was measured by the superoxide dismutase-
inhibitable reduction of ferricytochrome c (Sigma) (Spisani
et al, 1996) modified for microplate-based assays. The tests
were carried out in a final volume of 200 ml containing
4 × 105 neutrophils, 100 nmol cytochrome c and KRPG. At
zero time the stimulant was added and the plates (Falcon
Microtest III, Becton Dickinson Labware, Milano, Italy)
were incubated into a microplate reader (Ceres 900, Bio-
TeK instruments Inc.) with the compartment T set at
378C. Absorbance was recorded at wavelengths of 550
and 468 nm. Differences in absorbance at the two wave-
lengths were used to calculate nmoles of O¹2 produced,
using a millimolar extinction coefficient for cytochrome c
of 15·5.
The stimulants employed were phorbol 12-myristate
13-acetate (PMA, Sigma) 100 ng/ml and fMLP 10¹6 M in
KRPG. Neutrophils were preincubated with 5 mg/ml cyto-
chalasin B (Sigma) for 5 min prior to activation by fMLP.
Results were expressed as net nmoles of O¹2 /2 × 106 cells/
5 min. Assays were currently done in triplicate for each
experimental condition. PMA stock solution of 1 mg/ml in
DMSO was diluted before use in KRPG.
Granule enzyme assay. Release of neutrophil granule
enzymes was evaluated by determining lysozyme activity
(Spisani et al, 1997) modified for microplate-based assays.
3 × 106 cells were incubated in microplates wells in the
presence of the stimulus for 15 min at 378C. The plates were
then centrifuged for 5 min at 400 g and the lysozyme was
quantified nephelometrically by the rate of lysis of cell wall
suspension of Micrococcus lysodeikticus (Sigma). Reaction
rate was measured with a microplate reader at 465 nm.
Enzyme was expressed as a net percentage of total enzyme
content released by 0·1% Triton X-100. Total enzyme
activity was 85 61 mg/1 × 107 cells/min. The degranulating
agents used were PMA 0·1 mg/ml and fMLP 10¹6 M, in
KRPG. Cells were preincubated with cytochalasin B 5 mg/ml
for 15 min prior to activation by fMLP. Assays were
performed in triplicate for each experimental condition.
McAb treatment. When appropriate, cells were incubated
at 208C for 30 min with 3B10 or VIM5 McAbs, washed twice
with KRPG and then evaluated for cell functionality. The
controls were without McAbs, with an irrelevant mouse
IgG1 or IgG2a.
Chromosome analysis. Cytogenetic studies of leukaemic
cells were performed at diagnosis to detect the presence of
structural or numerical abnormalities. It was based on both
a direct technique or a short-term culture. In some cases
synchronization with methotrexate and thymidine was
carried out. In all cases G-binding was applied, and
karyotypes were expressed according to the International
System for Human Cytogenetic Nomenclature. The presence
of three or more events of translocation or non-disjunction in
the same clone was defined as complex karyotype (Castoldi &
Cuneo, 1996).
Statistical analysis. UPA-R expression and clinical and
biological characteristics were compared using parametric
and non-parametric statistics (Student’s t test, Wilcoxon test,
linear regression model).
RESULTS
Quantification of UPA-receptor in normal haemopoietic cells
The reactivity with UPA-R in haemopoietic cells from 15
healthy donors are shown in Table I. Briefly, 3B10 and VIM5
Table I. Flow cytometry quantification of UPA-R expression in normal haemopoietic cells using two different CD87 McAbs.
3B10 McAb VIM5 McAb
(% positive cells;* MESF/cell × 103; (% positive cells;* MESF/cell × 103;
Cell population ABC/cell × 103; mean (range)†) ABC/cell × 103; mean (range)†)
PB neutrophil granulocytes 99·3%; 32·8 (24·8–37·5); 3·5 (2·9–4·2) 99·1%; 31·2 (24·2–35·7); 3·6 (2·5–4·0)
PB monocytes 99·4%; 31 (19·8–37·1); 3·3 (2·5–3·7) 99·2%; 29·7 (7·4–36·2); 2·9 (2·3–3·6)
BM myeloid precursors 96%; 34·9 (11·9–52·6); 5·5 (3·4–13·6) 97·3%; 28·6 (17·1–45·7); 3·4 (2·8–9·9)
BM monocytic precursors 98·2%; 33·5 (20·5–58·5); 5·0 (3·7–13·5) 97·5%; 30·2 (18·3–48·9); 3·7 (3·0–11·1)
BM CD34þ cells <0·5% <0·5%
PB mobilized CD34þ cells <0·2% <0·2%
BM, bone marrow; PB, peripheral blood.
* Data are expressed as a mean of positive cases. Cells from 15 healthy adult subjects were analysed.
† Range for ABC and MESF values is referred to positive cases.
McAbs were found to be positive in over 99% of both
monocytes and neutrophil granulocytes. Using the reference
VIM5 and 3B10 UPA-R McAbs, the number of receptors
expressed by monocytes and neutrophil granulocytes was
found to be similar, whereas resting B and T lymphocytes
were unreactive with both UPA-R McAbs.
As far as the cytofluorimetric expression of UPA-R in bone
marrow cells is concerned, we found that myeloid precursors
(promyelocytes, myelocytes and metamyelocytes) showed
intermediate levels of UPA-R (range of ABC/cell using 3B10:
3·4 × 103 to 13·6 × 103 ABC), as demonstrated by one-
(using the QIFIKIT assay), two- and three-colour fluorescence
analysis (CD13/FITC, UPA-R/PE, CD45/PerCP; HLA-DR/FITC,
CD87/PE, CD45/PerCp). In contrast, about 40% of bone
marrow neutrophils (mean 42·1% 613·4 SD) lacked surface
UPA-R. Monocytes and their precursors showed similar levels
of UPA-R (ABC range 3·7 × 103 to 13·5 × 103), as assessed by
single and multicolour fluorescence experiments based on the
use of the following McAbs: CD45/FITC, UPA-R/PE, CD33/
PerCp or CD4/PE-Cy5).
The progenitor cell compartment was defined by the
immunophenotypic expression of CD34 antigen. The flow
cytometry analysis of purified CD34þ cells obtained from the
bone marrow or peripheral blood (collected after G-CSF-
induced mobilization of peripheral blood stem cells) of
healthy adult subjects showed that >99% of the cells
lacked the UPA-R (Table I).
Regarding the reactivity of the two CD87 McAbs used in
this study, a positive correlation between expression of VIM5
and 3B10 McAbs in normal cells was found (r ¼ 0·95).
Detection of cytoplasmic UPA-R
Fixation and permeabilization of normal monocytes and
neutrophils increased the amount of detectable UPA-R in all
cases examined (n ¼ 3). The total amount of UPA-R detected
by flow cytometry in the two cell populations was,
respectively, 1·8 and 1·3 times higher than its surface
expression evaluated on unfixed cells (mean MESF/cell
for surface UPA-R of monocytes: 9·6 × 103; mean MESF/
cell for monocyte cyUPA-R: 17·4 × 103; mean MESF/cell
for surface UPA-R of neutrophils: 11·1 × 103; mean
MESF/cell for neutrophil cyUPA-R: 14·6 × 103), thus
revealing intracellular UPA-R pools.
Functional studies
Effects of anti-UPA-R McAbs on neutrophil locomotion. To
determine whether neutralization of UPA-R by specific
McAbs affects neutrophil locomotion, random movement,
chemokinesis and chemotaxis were assessed.
When neutrophils were pretreated with saturating con-
centrations of McAbs 3B10 or VIM5 for 20 min at 378C,
VIM5 influenced random movement with an increment of
about 60% (P<0·01) of the basal value of the control
(Fig 1A). In addition, when equal concentrations of the
chemotaxin fMLP was present in both upper and lower
chambers, non-oriented locomotion was significantly acti-
vated, whereas the treatment with 3B10 McAb had no effect
on cell chemokinesis, as detected by checkerboard analysis
(not shown). In similar experiments we evaluated the effect
of the treatment with anti-UPA-R on chemotaxis induced by
both fMLP and casein.
As shown in Figs 1B and 1C, the two antibodies reduced,
in a dose–response way, the chemotaxis activated by both
fMLP and casein (P<0·05); 3B10 and VIM5 McAbs had no
intrinsic chemotactic activity.
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Fig 1. Effect of anti-UPA-R McAbs on neutrophil locomotion. Random locomotion was assayed in the absence of chemotaxins (panel A). Directed
locomotion or chemotaxis was evaluated by adding fMLP 10¹6 M (panel B) or casein 2 mg/ml (panel C) to the lower compartment. The actual
control of chemotaxis induced by fMLP or casein was 78 63 mm or 87·6 6 2 mm, respectively. Each value represents the average 6SEM from eight
to 10 separate experiments carried out in triplicate.
Fig 2. Effect of anti-UPA-R McAbs on neutrophil degranulation.
Granule secretion was induced by fMLP 10¹6 M (panel A) or PMA
100 ng/ml (panel B). The actual control of lysozyme release by fMLP
or PMA was 45 6 4% or 52 6 5% of release/3 × 106 cells/10 min,
respectively. Each value is the average 6SEM from eight to 10
separate experiments carried out in triplicate.
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Table II. Flow cytometry quantification of expression levels of UPA-R in acute leukaemic blasts of myeloid and B-lymphoid lineage.
3B10 McAb VIM5 McAb
(% positive cases;* MESF/cell × 103; (% positive cases;* MESF/cell × 103;
AML FAB subtype‡ ABC/cell × 103: mean (range §)) ABC/cell × 103: mean (range))
AML M0 (n ¼ 7) 57%; 9·6 (1·5–26·2); 2·0 (1·0–6·9) 43%; 14·0 (0·8–31·4); 2·9 (1·1–7·8)
AML M1 (n ¼ 12) 67%; 10·3 (1·8–36·1); 2·5 (1·2–13·6) 50%; 12·9 (1·0–30·2); 2·7 (1·0–11·5)
M2 (n ¼ 20) 70%; 8·4 (1·1–36·2); 2·4 (1·1–14·3) 50%; 11·4 (1·4–31·1); 2·6 (1·3–12·9)
M3 (n ¼ 4)§ 100%; 12·2 (2·1–30·2); 3·0 (1·4–10·1) 75%; 12·8 (1·2–35·1); 3·3 ( 1·2–11·0)
M4 (n ¼ 11) 91%; 21·9 (1·5–53·1); 5·6 (1·2–17·3) 81%; 13·9 (1·2–64·2); 4·5 (1·0–19·5)
M5 (n ¼ 20) 100%; 52·7 (6·1–220); 12·9 (2·9–56·4) 100%; 61·2 (5·5–231); 14·4(2·2–60·4)
B-lineage ALL (n ¼ 24) 12%; 3·1 (1·3–6·0); 2·0 (0·9–2·8) 12%; 2·3 (1·5–4·6); 1·4 (0·9–2·0)
Biphenotypic acute leukaemia (n ¼ 3) 66%; 2·5 (1·7–3·2); 1·3 (0·9–1·5) 33%; 3·0; 1·4
* Data are expressed as mean percentages of positive cases. † ABC range is referred to positive cases. ‡ FAB (French–American–British)
subtype. § Cell positivity was evaluated on leukaemic promyelocytes.
Fig 3. Flow cytometry analysis of UPA-R on blasts from a patient with AML M5. (A) Dot plot showing the light scattering characteristics of the
cells analysed. Histogram distribution of cells stained with 3B10 (B) and VIM5 (C) McAb. IgG2a and IgG1 ¼ isotypic controls; ABC ¼ antibody
binding capacity.
Effects of anti-UPA-R on enzyme degranulation. The capacity
of anti-UPA-R McAbs to affect the release of lysozyme from
specific granules was assessed. As shown in Fig 2A, the
response to fMLP stimulation seemed dependent on McAb
specificity, since only VIM5 exhibited a 50% inhibition
(P<0·05) in enzyme exocytosis, whereas the response to
PMA stimulation (Fig 2B) showed a significant reduction
(P<0·01) in degranulation in cells treated with 3B10 or
VIM5 McAbs. The two McAbs did not affect enzyme release
from granules, in the absence of stimuli.
Effects of anti-UPA-R on neutrophil superoxide production.
To elucidate whether neutrophil respiratory burst
depended on the presence of UPA-R, cells were treated with
McAbs and then stimulated by fMLP and PMA for 5 min and
10 min, respectively. No difference in superoxide anion
generation was seen in these Mc-Ab-treated cells (not
shown).
Quantitative analysis of UPA-R expression in acute leukaemic
blasts
Acute myeloid leukaemia. Cell positivity for UPA-R varied
significantly from case to case, depending on the FAB
subtype, type of anti-UPA-R McAb used, clinical phase of
the disease, and type of the sample analysed (peripheral
blood v bone marrow). By looking at the expression of CD87
in the whole series of AML patients (n ¼ 74), we found that
81% of AML patients showed reactivity for the 3B10 McAb,
and VIM5 McAb was positive in 69% of the cases examined
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Fig 4. Quantitative analysis of UPA-R on leukaemic cells from a patient with AML FAB M0. Upper left panel: dot plot generated by combining side
scatter versus forward scatter (logarithmic scale); upper right panel: calibration curve generated using Dako QIFIKIT microbeads. Histogram
distribution of cells stained with 3B10 (lower left panel) and VIM5 (lower right panel) McAb. A discordant reactivity of the two UPA-R McAbs was
observed. IgG2a and IgG1¼ isotypic controls; ABC ¼ antibody binding capacity.
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(Table II). Among the positive cases (range of ABC/cell:
1·0 × 103 to 60·4 × 103) the number of UPA-Rþ blasts was
similar, with 3B10 and VIM5 McAbs (mean percentage of
positivity: 76·6 6 39·1 SD, and 69·2 6 36·6 SD, respec-
tively), irrespective of the FAB subtype (Table II).
The highest expression of UPA-R was seen in patients
classified as M5 FAB subvariety (mean ABC/cell for the 3B10
McAb: 12·9 × 103; mean ABC/cell for VIM5 McAb:
13·4 × 103) (Fig 3), whereas the lowest expression was
found in the M0 FAB category (mean ABC for 3B10:
2·0 × 103) (Fig 4). Two- and three-colour analyses further
revealed that >70% UPA-Rþ blasts from >60% patients
belonging to the M1–M2 FAB subtype showed expression for
CD34, c-kit, HLA-DR, CD13, CD33, CD38, MPOhigh,
lysozymelow antigens (Fig 5). Within the M4 and M5 FAB
subtypes, UPA-Rþ blasts co-expressed CD11c, CD14, CD13low,
CD33high, lysozymehigh, myeloperoxidase (MPO)low/negative in
most cases (Fig 6).
Regarding the reactivity of the two CD87 McAbs used in
this study, a positive correlation between the expression of
VIM5 and of 3B10 McAbs in leukaemic cells was found
(r ¼ 0·87). However, in five cases (AML, n ¼ 4; ALL, n ¼ 1)
the number of UPA-Rþ blasts detected by the two CD87
McAbs was significantly different (Fig 4).
The quantitative analysis of UPA-R in acute leukaemia
further showed that the number of receptors expressed by
leukaemic cells from 6/74 (8·1%) AML patients was above
the highest values seen in normal samples (>15 × 103 ABC/
cell; range: 22·6 × 103 to 60·4 × 103). All these cases were
classified as AML, M5 FAB subtype (Table II, Fig 3).
Fig 5. Flow cytometry dot plots of AML cells (FAB M1). Myeloperoxidase (MPO) and UPA-R (VIM5 McAb) antigen dual staining showing a strong
positivity for the two markers in 51% of the cells (B). (C) Two-colour fluorescence analysis using lysozyme/FITC and UPA-R-VIM 5/PE showed a
weak-intermediate expression for lysozyme on leukaemic cells derived from the same patient described in panels A and B. Panel A shows the
light-scattering characteristics of the same cells.
Furthermore, CD34 antigen was expressed (>20%) by
CD87þ leukaemic blasts from 16 patients (20%) with
AML. Coexpression of CD34 and UPA-R was associated
with FAB M5 morphology (three cases), FAB M0 (two
cases), FAB M1 (five cases), FAB M2 (three cases) and FAB
M4 (two cases).
Interestingly, in six AML patients, a comparative analysis
of UPA-R expression between blood and bone marrow
blasts revealed the number of UPA-R expressed by
peripheral blood leukaemic cells to be significantly higher
(mean ABC/cell for 3B10 McAb: 14·7 × 103; range ABC/
cell: 6·2–45·2 × 103) than that of bone marrow cells (mean
ABC/cell: 5·8 × 103; range ABC/cell: 3·5–24·1 × 103). A
similar pattern was observed for the percentage of positivity
for UPA-R, which was higher in blood blasts (95%) than in
bone marrow cells (61%), despite the higher proportion of
acute leukaemic blasts (as assessed by morphology and
multicolour analysis with a flow cytometer) in the bone
marrow.
Furthermore, in five AML patients (FAB M1: two cases;
M4: two cases; M5: one case), relapsed disease following
induction-consolidation chemotherapy was characterized by
a marked increase in the number of UPA-R (mean pre-
treatment ABC values for 3B10 McAb: 3·9 × 103/cell; mean
ABC values for 3B10 McAb in relapsed disease: 7·1 × 103/
cell). No change in the FAB morphology was noticed in
relapsed disease.
The statistical analysis of our data did not show any
correlation between number of UPA-R, cell cycle phases,
and/or DNA content of AML cells (data not shown).
Clinical and cytogenetic characteristics of AML with higher
expression of UPA-R. On the basis of the expression levels for
CD87 in leukaemic cells, it was possible to identify 14 AML
patients whose blasts had UPA-receptors of more than
12 × 103/cell. 57% (8/14 cases) of these patients had FAB
M5 morphology, whereas the remaining 43% were classified
as M1 (n ¼ 1), M2 (n ¼ 2), M3 (n ¼ 1), or M4 (n ¼ 2) FAB
categories; they showed multiple mucocutaneous infiltrative
lesions (n ¼ 10), hepatosplenomegaly (n ¼ 11), generalized
peripheral lymphadenopathies (n ¼ 3), musculo-skeletal
involvement (n ¼ 2), infiltration of Waldeyer ring, tonsillitis,
pharyngitis (n ¼ 4), central nervous system and/or menin-
geal involvement (n ¼ 4) and a higher leucocyte count
(>40 × 109/l; mean 59 × 109/l). The frequency of these
clinical manifestations was significantly higher in the patient
group with bright expression of UPA-Rþ, compared to AML
cells with lower levels of protease (Table III).
Clonal chromosome changes were seen in all but one of
the 14 AML patients with UPA-Rbright phenotype
(>12 × 103 ABC/cell), seven of whom had complex
karyotypes (three or more concomitant chromosome
abnormalities). Unidentified marker chromosomes were
found in four patients (29%). The 13 cases with karyotype
abnormalities included six cases with involvement of
chromosome 11 (11 q¹; t(9;11), þ 11); four with
abnormalities of chromosome 5 (¹5; 5qþ), three with
involvement of chromosome 13 and/or chromosome 3
(3q¹, inv 3), or chromosome 10 (10p, þ 10). Aberrations
of chromosomes 2, 4, 8, 9,14, 15, 16, 17 and 22 were
seen in only one or two patients.
In contrast, only 71% of 60 AML patients having either
low or no expression for UPA-R showed abnormal karyo-
types, of which seven (11%) had complex karyotypes.
The incidence of chromosome changes in the AML
group with high UPA-R expression was significantly
higher than that of the UPA-Rdim/neg AML subgroup
(P<0·001). Furthermore, since it has been shown that the
CD87 gene is localized on chromosome 19, band q13, we
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Fig 6. Flow cytometry dot plots of AML bone marrow cells (FAB M5). Left panel: light scattering properties of bone marrow cells from the AML
patient. Right panel: lysozyme and UPA-R (VIM5 McAb) antigen dual staining showing a strong positivity for the two markers in 48% of the cells.
The same cells (UPA-Rþ/Lysoþ) resulted MPO negative. Lyso ¼ lysozyme McAb.
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looked for possible correlations between UPA-R expression
and involvement of chromosome 19. Abnormalities of
chromosome 19 were solely observed in the UPA-R
negative/low AML group (mean ABC/cell: 1·6 × 103/cell);
range: 1·0–2·5 × 103/cell), where 5/21 cases (25%) revealed
this aberration either alone (þ19: four cases; inversion-
insertion (19) (q13 p13 p12): one case) or in combination
with other chromosome changes. On the contrary, none of the
AML patients having higher UPA-R expression showed
alterations of chromosome 19.
The frequencies of the more common chromosome
aberrations in UPA-Rþbright v UPA-Rneg/low AML are given
in Table IV.
Detection of cytoplasmic UPA-R. Fixation and permeabiliza-
tion of leukaemic cells from AML patients increased the
amount of detectable UPA-R in 70% of the cases studied.
Using 3B10 McAb, the total amount of UPA-R detected by
flow cytometry was 3·3 times higher than its surface
expression evaluated on unfixed cells (mean MESF/cell
for surface UPA-R: 2·9 × 103/cell; mean MESF/cell for UPA-
R cytoplasmic pool: 9·7 × 103/cell), thus revealing
intracellular UPA-R pools.
Table IV. Cytogenetic features in UPA-Rþ bright (>12 × 103 ABC/cell) and UPA-Rneg/low (<12 × 103 ABC/cell) AML.
UPA-Rþ bright UPA-R¹neg/low
(>12 × 103 ABC/cell) AML (<12 × 103 ABC/cell) AML
(n ¼ 14) (n ¼ 60)
No. of cases No. of cases
Karyotype (FAB category) % (FAB category) %
Overall frequency of 13/14 93% 43/60 71%
chromosome abnormalities
Normal 1/14 7% 17/60 29%
t(8;21)(q22;q22) — — 4/60 (M2) 7%
t(15;17) (q21;q21) 1/14 (M3) 7% 3/60 (M3) 5%
11q¹/t(9;11) 4/14 (M5) 28% 6/60 (M5) 10%
13q abnormalities 1/14 (M5) 7% 5/60 (M1, M2, M4) 8%
¹5/5q¹ 4/14 (M0, M1, M4) 29% 9/60 (M0, M1, M4) 15%
¹7/7q¹ 1/14 (M1) 7% 8/60 (M0, M1, M2, M4) 13%
þ8 1/14 (M5) 7% 8/60 (M0, M1, M2, M4, M5) 13%
Complex karyotype * 7/14 (M0, M1, M5) 50% 7/60 (M0, M1, M4, M5) 11%
Abnormalities of chromosome 19† — — 5/60 (M1, M2, M4, M5) 8%
* In several cases the single chromosome aberrations were associated with multiple chromosome changes, thus forming
a complex karyotype.
† þ19; inv ins(19)(q13;p13;p12), as additional aberration within a complex karyotype.
Table III. Patient characteristics in UPA-Rþ bright (>12 × 103 ABC/cell) and UPA-Rneg/low (<12 × 103 ABC/cell) AML.
UPA-Rþ bright UPA-Rneg/low
(>12 × 103 ABC/cell) AML P value (<12 × 103 ABC/cell) AML
No. of cases 14 60
Male/female 8/6 ns 34/26
WBC × 109/l (median) 59 0·0001 14
Plt × 109/l (median) 41 ns 47
Hb (g/dl) (median) 8·1 ns 7·8
FAB M5 subtype (n (%)) 8 (57%) 0·01 12 (20%)
Multiple mucocutaneous infiltrative lesions (n (%)) 10 (71%) 0·001 12 (20%)
Hepatosplenomegaly (n (%)) 11(79%) 0·005 20 (33%)
Generalized lymphadenopathy (n (%)) 3 (21%) 0·01 1 (1·6%)
CNS involvement (n (%)) 3 (21%) 0·001 None
Meningeal involvement (n (%)) 4 (29%) 0·001 1 (1·6%)
Musculo-skeletal involvement (n (%)) 2 (14%) 0·01 None
Waldeyer’s ring involvement (n (%)) 4 (29%) 0·001 2 (3%)
ns ¼ not significant.
Acute lymphoblastic leukaemia. 12% (3/24) of ALL cases
were UPA-R positive (Table II). However, the number of
receptors expressed by leukaemic blasts from all ALL cases
was extremely low (<3 × 103 ABC/cell). One patient showed
co-expression of myeloid (CD13 and CD33) and lymphoid
markers (CD10, CD19, CD79a, CD22), and was classified as
common-type ALL with minimal phenotypic deviation,
according to the EGIL criteria. The other two cases had a
pro-B phenotype (CD19þ, cyCD22þ, CD79aþ, CD34
þ
,
CD10¹, cm¹, SIg¹); however, lymphoid blasts were CD13þ
in one patient.
Biphenotypic leukaemias. Three cases were classified as
byphenotypic acute leukaemia: these comprised two cases
with a myeloid and B-lymphoid phenotype and one case with
a T-lymphoid and myeloid phenotype. All these cases had
scores higher than 2 for the lymphoid and myeloid lineages,
according to the criteria of the EGIL group. Two out of three
cases were UPA-R positive using 3B10 McAb, but the level of
antigen expression was low (mean ABC/cell 1·2 × 103)
(Table II).
DISCUSSION
The cellular expression and clinical significance of the UPA
receptor was investigated in acute leukaemic blasts and
normal haemopoietic cells through the use of a flow
cytometer and appropriate standards, which enabled a
reliable measurement of antibody binding capacity and
MESF values in the various cell types.
In previous studies it has been shown that UPA-R may be
involved in cellular extravasion and in metastasis formation
(Cao et al, 1995; Todd & Petty, 1997). In leukaemia,
overexpression of UPA-R and/or other components of this
system was found to consume plasma inhibitors, producing a
tendency to haemorrhage (Todd et al, 1995; Lijnen, 1996;
Bennett et al, 1997). The evidence that UPA-R and its ligand
UPA are involved in the metastatic potential of tumour cells
derives from a wide range of observations, including (i) a
close relationship between oncogenic transformation and
UPA synthesis, and between UPA and cellular invasion as
well as metastasis in several model systems (melanoma,
neuroblastoma, breast, colon and prostate carcinoma, etc.);
(ii) the inhibition of these processes by anticatalytic McAbs to
UPA; and (iii) the histochemical localization of UPA at the
invasive fronts of tumours (Bu et al, 1994; Lijnen, 1996;
Todd et al, 1995). However, little is known about the cellular
expression and clinical significance of the UPA-receptor in
leukaemic cells from patients with acute leukaemia (Knapp
et al, 1994).
In this study we have demonstrated that both neutrophil
granulocytes and monocytes taken from the peripheral blood
of healthy subjects had detectable levels of UPA-R, whereas
resting B and T lymphocytes lacked CD87 in all the cases
examined. In healthy subjects, reactivity for UPA-R McAb
was also detected on bone marrow CD34-negative myelo-
monocytic precursors (promyelocytes, myelocytes, meta-
myelocytes and promonocytes), whereas BM and mobilized
peripheral blood CD34þ progenitors were UPA-R negative,
supporting the concept that UPA-R expression is a stage-
specific feature of late myelomonocytic cells. The lack of UPA-
R in a significant number of bone marrow neutrophil
granulocytes may be explained by the peculiar homing
characteristics of this cell subset, possibly correlated to an
unfinished degranulation of surface proteins.
In a second set of experiments we attempted to confirm
whether UPA-R had a role in mediating neutrophil functions
(Gyetko et al, 1994, 1995). Oriented locomotion induced by
different chemotaxins, such as fMLP and denatured casein,
was significatively diminished when UPA-R was neutralized
by McAbs. Similarly, lysozyme release by granules stimulated
with fMLP or PMA was markedly blocked. The inhibitory
effect does not depend on either the presence of membrane
agonist receptor or the intracellular pathway activated by
chemotaxins. In fact, although fMLP possesses at least two
receptor isoforms (Ye & Boulay, 1997) (each one able to
induce a specific biological response), denatured peptides
or proteins, such as casein, could recognize neutrophil
surface by aspecific hydrophobic interactions. These results,
however, further support those of Gyetko et al (1994),
indicating that UPA-R has a structural and functional role in
the cytoskeleton reorganization required for cell activation.
The observation that UPA-R, in our hands, seemed not to
be involved in NADPH oxidase activation was not in contrast
with the findings of Cao et al (1995) who showed the priming
effect of UPA of fMLP-triggered superoxide generation, since
in our assay conditions, cytochalasin B was added to
potentiate the ability of fMLP to produce superoxide anion,
and probably the priming effect mediated by UPA-R ligands
was dimmed. Moreover, the amount of O¹2 produced was
determined at 5 min, and not at 30 min, when stimulated
with fMLP. This observation, together with the lack of UPA-R
involvement in NADPH activation, may exclude a receptor–
receptor association able to block the second messenger
pathway, but may support the hypothesis that UPA-R is
involved in the cytoskeletal reorganization required for cell
movements, namely locomotion and degranulation (Gyetko
et al, 1994).
As far as the expression of UPA-R in blast cells is
concerned, we found that 81% of AML patients showed
reactivity for the anti-UPA-R 3B10 McAb, but only 67% for
VIM5 McAb. The number of positive cases and the level of
expression was significantly higher in AML patients belong-
ing to the FAB M5 subgroup, thus supporting the concept
that a close association between monocytic commitment and
expression of UPA-R may exist. Experiments of two- and
three-colour fluorescence further showed that FAB M1–M3
AML were characterized by low-intermediate expression for
UPA-R and lysozyme, and bright-intermediate expression for
MPO, whereas the M5 FAB subvariety had high-intermediate
levels of UPA-R and lysozyme, and little or no expression of
MPO. On the basis of these data, it can be postulated that the
combined use of UPA-R, MPO and lysozyme McAbs may
provide useful information for the diagnosis of acute
leukaemia, and for the distinction of myeloid from monocyte
leukaemias (Knapp et al, 1994; Lanza et al, 1997b).
Interestingly, since the co-expression of UPA-R and CD34
was not found in normal haemopoietic cells, this marker
combination could be used for detecting leukaemic cells in
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remission bone marrows and in peripheral blood leukapher-
sis products. Furthermore, the number of UPA-R expressed
by leukaemic cells from 8·1% of AML patients was above the
highest values seen in normal samples, making it a feasible
marker, even alone, for monitoring the minimal residual
disease (MRD) in a subset of AML. Concerning the expression
of these markers in AML with minimal evidence of myeloid
differentiation, we found that four out of seven cases of FAB
M0 AML were positive for the UPA-R McAb. Only one of them
showed reactivity for the anti-MPO McAb, and none for
lysozyme, thus indicating that CD87 may have a role in the
recognition of FAB M0 AML.
We have also shown that the great majority of leukaemic
blasts from AML patients had intracellular stores for UPA-R,
as demonstrated by the comparison of surface expression
evaluated on unfixed cells and total antigen content in
permeabilized cells. This finding is in agreement with the
observation that, in resting neutrophils, UPA-R are stored in
three distinct intracellular compartments (secretory vesicles,
specific granules and gelatinase granules) (Plesner et al,
1994; Borregaard & Cowland, 1997). Functional studies
have also shown that, after activation, the intracellular pools
of UPA-R may translocate to the cell surface (Plesner et al,
1994; Borregaard & Cowland, 1997). Our own studies
provide evidence that both neutrophils and monocytes
contain an intracellular pool of UPA-R detectable by flow
cytometry on permeabilized cells.
Another interesting finding, which may have clinical
implications, is represented by the marked increase in the
number of UPA-R receptors in relapsed disease after
induction-consolidation chemotherapy, thus indicating that
the quantitative analysis of this receptor may be of value for
the monitoring of AML patients.
No correlation was found between number of UPA-R,
kinetic status and DNA content, whereas the frequency of
chromosome abnormalities was much higher in AML cells
overexpressing UPA-R than in AML blasts having little or no
expression of UPA-R, indicating that the expression of this
protease may increase the aggressiveness of the disease.
In contrast, only 12% (3/24) of ALL patients were CD87
positive; however, the degree of positivity was considerably
weaker in ALL blasts than in AML cells, allowing us to
speculate that this molecule may help in the distinction of acute
myeloid leukaemias from lymphoid malignancies. However,
the specificity of this marker for the myeloid commitment of
the blasts needs to be confirmed using larger numbers of
acute leukaemia patients. Furthermore, two out of three
byphenotypic leukaemias and one out of three cases of AML
with minimal phenotypic deviation showed positivity for CD87.
The diagnostic usefulness of UPA-R McAbs in the classifi-
cation of byphenotypic and undifferentiated acute leukaemias
deserves careful evaluation in prospective future studies.
A close analysis of our data further shows a certain
variability in the reactivity of leukaemic cells with the two
UPA-R McAbs. The significance of this discrepancy is
uncertain; nevertheless, it is possible to speculate that this
group of McAbs recognizes a distinct epitope of the molecule
(Todd et al, 1995). Competitive binding assays and extensive
immunoprecipitation studies have confirmed the recognition
of different epitopes in close proximity of, or within, the UPA
binding domain of the urokinase receptor (Garni-Wagner &
Todd, 1995); the biological relevance of such a finding is still
under evaluation.
A possible correlation between UPA-R expression and the
clinical features of acute leukaemias was observed in
patients having a number of UPA-receptors superior to
12 × 103 ABC/cell who, irrespective of the FAB category,
showed a greater tendency to cutaneous and tissue
infiltration, together with a higher leucocyte count, as
compared to AML patients whose blasts were UPA-R
negative or dimly positive. Since proteolytic enzymes,
such as UPA, play a key role in the dissolution of the
extracellular matrix and in facilitating the cell egress from
the bone marrow, it is conceivable that the expression of
the UPA-R could contribute to the invasive properties and,
possibly, the metastatic potential of leukaemic cells in a
subset of AML. Further evidence in favour of the role of
UPA-R in facilitating leukaemic cell extravasation from the
bone marrow into the circulation derives from the demon-
stration that both the percentage of positivity and the
surface antigen density of UPA-R was significantly higher in
peripheral blood AML cells than in bone marrow blasts.
Furthermore, the bright expression of UPA-R on AML
blasts was associated with a high incidence of chromosome
abnormalities, most of which were complex. Interestingly,
within M5 AML patients, who were cytogenetically char-
acterized by either the t(9;11) or 11q¹ abnormalities, two
groups could be recognized, i.e. those who showed a strong
expression of UPA-R and those whose blast cells were dimly
positive for UPA-R. However, since in the M5 FAB group,
patients carrying 11q¹ abnormalities have a variable
clinical outcome, It can be speculated that the combination
of higher UPA-R positivity, abnormalities of chromosome 11
and M5 FAB morphology may identify a peculiar subset of
AML characterized by distinct morpho-immunological and
cytogenetic features, and a more aggressive clinical course.
Moreover, although the incidence of complex karyotypes was
significantly higher in the AML patient group with UPA-
Rbright phenotype in comparison with that of UPA-Rneg/dim
AML, no correlation was found between FAB category and
the occurrence of complex chromosome aberrations.
In conclusion, cellular UPA-R expression was variable,
ranged from undetectable (ALL and a minority of AML) to
very high intensities in M5 AML, and was also documented
in >50% M0 AML, thus supporting the concept that UPA-R
may be considered a specific and rather sensitive marker to
detect leukaemic cells committed to the myeloid lineage. As a
consequence, the inclusion of this marker for the immuno-
phenotype diagnosis of acute leukaemia is recommended,
even if a closer analysis of its expression in a large prospective
study is needed before drawing any definitive conclusion on
this matter.
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